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Abstract (250 words) 
Objectives: Raynaud’s phenomenon (RP) in systemic sclerosis (SSc) could be influenced by 
clinical phenotype, environmental factors e.g. season and personal factors e.g. coping 
strategies and ill-health perceptions. We explored the relative influence of a range of 
putative factors affecting patient-reported assessment of SSc-RP severity. 
Methods: SSc patients were enrolled at UK and US sites. Participants completed the 2-week 
Raynaud’s Condition Score (RCS)-diary alongside collection of patient demographics, clinical 
phenotype, the Coping Strategies Questionnaire, Pain Catastrophisation Scale, Scleroderma 
Health Assessment Questionnaire (SHAQ) and both patient/physician visual analogue scale 
(VAS) assessments for RP, digital ulcer disease and global disease. Environmental 
temperature data was obtained at each site. A second RCS-diary was completed 6-months 
after enrolment.   
Results: We enrolled 107 patients (baseline questionnaires returned by 94). There were 
significant associations between RCS-diary parameters and both catastrophisation and 
coping strategies. There were significant associations between RCS-diary outcomes and 
both environmental temperature and season of enrolment. Age, disease duration, sex, 
disease subtype, smoking and vasodilator use were not associated with RCS-diary outcomes. 
The best fitting multivariate model identified the patient RP VAS, the SHAQ pain VAS and 
the SHAQ gastrointestinal VAS subscales as the strongest independent predictors of the RCS 
score. 
Conclusions: Patient-reported assessment of SSc-RP severity is associated with a number of 
factors including pain, catastrophisation and coping strategies.  The effects of seasonal 
variation in environmental temperature on SSc-RP burden has implications for clinical trial 
Factors influencing RCS-diary outcomes in SSc 
 
  4 
 
design. Treatments targeting SSc-RP pain and the development of behavioural interventions 
enhancing coping strategies may reduce the burden of SSc-RP.  
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Introduction 
Raynaud’s phenomenon (RP) describes episodic excessive vasoconstriction of the digital 
microvasculature in response to cold exposure and/or emotional stress (1). It is the 
commonest manifestation of systemic sclerosis (SSc) and a major cause of disease-related 
morbidity (2-4). The severity of the underlying digital obliterative microangiopathy and 
relative efficacy of vasodilator medications are likely to contribute to the wide inter-
individual variation in the severity and impact of SSc-RP (5). A number of additional factors 
contribute to SSc-RP burden including seasonal variation in environmental exposure to cold 
and the positive steps taken by patients to avoid or ameliorate the conditions responsible 
for SSc-RP symptoms (4, 6, 7). Symptom habituation and adaptation further moderate the 
impact of SSc-RP symptoms (4). The Raynaud’s Condition Score (RCS) diary is currently the 
preferred endpoint for SSc-RP clinical trials (8). Captured over a 1-2 week period, the RCS 
diary provides an estimate of the mean daily frequency of SSc-RP attacks, the mean daily 
duration of SSc-RP attacks and a mean daily assessment of the impact /severity of SSc-RP 
symptoms (applied as either an 11-point numeric rating scale [NRS] or 100mm visual 
analogue scale [VAS]). The mean daily frequency and duration of RP attacks during 2-week 
RCS diary collection has been relatively consistent across studies (between 3-4 attacks per 
day with a mean daily aggregate duration of 30-90 minutes/day; equating to average attack 
duration of ~15-20 minutes per attack (3). Similarly, the mean RCS score in SSc patients is 
typically ~4.4/10 on an 11-point NRS (3). Much of this data has been obtained in clinical trial 
settings; typically undertaken during Winter and often mandating a minimum threshold 
number of RP attacks in the period prior to study entry (3, 13). Establishing treatment 
efficacy using RCS diary parameters has been challenging with clinical trials of promising 
vasodilator therapies yielding negative or modestly positive findings at best (9-13). The high 
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placebo response and poor agreement between RCS-diary parameters and objective 
assessments of digital perfusion have caused consternation (5, 14). Additional concerns 
about the RCS diary have been raised amongst patients and SSc experts (7, 15). A thorough 
understanding of the factors contributing to RCS diary outcomes could provide insight into 
its performance as an endpoint in clinical trials, influence future SSc-RP clinical trial design 
and support the development of novel approaches to SSc-RP management. The Raynaud’s 
Symptom Study (RSS) is a multi-center longitudinal study designed to assess the nature and 
determinants of RP symptoms in SSc. We have recentlyreported the clinical significance of 
RP symptom characteristics in SSc (16). This second report from the RSS focuses on the 
relative influence of putative factors including clinical phenotype, patient demographics, 
coping strategies, catastrophisation, and seasonal variation in environmental temperatures 
on patient-reported assessment of RP severity. 
Patients and Methods 
Patients 
 SSc patients fulfilling the 2013 American College of Rheumatology/European League 
Against Rheumatism classification criteria for SSc (17) were enrolled at routine clinical care 
visits from SSc clinics in Bath, United Kingdom (UK) and Utah, United States (US) between 
April 2015 and January 2017.  All patients were English speaking. The study received ethical 
approval at each site (Bath REC 15/LO/1521 and Utah IRB #80665) and all participants 
provided informed written consent. 
Clinician case report form (CRF) 
A clinician CRF collected information on patient demographics (age, sex, ethnicity, disease 
duration based on time since 1st non-RP symptom), smoking history, clinical phenotype and 
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autoimmune serology. The clinical phenotype sought documented evidence from the case 
notes of gastro-oesophageal reflux disease (GORD) symptoms, puffy fingers, sclerodactyly, 
digital ulcers (DU), digital pitting (DP), telangiectases, pulmonary arterial hypertension 
(PAH), interstitial lung disease (ILD) and autoantibody specificity. Relevant co-morbidities 
and vasoactive medication use were documented. Clinicians completed 100mm VAS scores 
physician global assessment, RP severity and DU severity.  
Patient questionnaires 
Each participant received a RSS questionnaire containing the Scleroderma Health 
Assessment Questionnaire (SHAQ), comprising the HAQ-Disability Index and SSc-specific 
150mm VAS subscales (18), the one-item coping skills questionnaire [CSQ] (19) (a validated 
abridged version of the original CSQ (20)), the pain catastrophisation scale [PCS] (21) and 
separate 100mm VAS assessments for SSc-RP severity, patient global assessment and DU 
severity (see supplementary material). The 7 items of the one-item CSQ are scored using a 
7-point NRS (0-6, ranging from “never do” to “always do that”) with each representing 
distinct domains pertaining to: Diverting Attention , Reinterpreting Pain Sensations , 
Catastrophizing , Ignoring Sensations , Praying and Hoping , Coping Self-Statements  and 
Increasing Behavioural Activities  (19, 20). Patients were dichotomised for each domain 
according to low coping strategies (score 0-2) and high coping strategies (score 3-6). The 13-
item PCS was developed to investigate mechanisms by which catastrophizing impacts on 
pain experiences (21). Each item is scored using a 5-point NRS (0-4, ranging from “not at all” 
to “all the time”). A composite score (0-52) was derived and a cut-off of 30 applied to 
dichotomise the group into copers and catastrophizers (based on earlier work identifying a 
score of 30 as corresponding to the 75th percentile in samples of chronic pain patients) (21). 
Subscales for rumination (items 8-11), helplessness (items 1-5, 12) and magnification (items 
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6,7,13) were also derived from the PCS as previously described (21). Participants were 
instructed on completion of the 2-week RCS diary from which we derived the mean daily 
RCS, mean daily frequency of RP attacks and mean aggregate daily duration of RP attacks 
(providing a minimum of 10 days [of 14] had been completed satisfactorily). Participants 
completed a second RCS diary 6 months following enrolment. 
Weather data 
The daily maximum and minimum temperature from Bath, UK and Salt Lake City, Utah, 
weather stations was obtained using UK Meteorological Office data for April 2015 through 
to July 2017.  
Statistical analysis 
Descriptive statistics are defined where applicable. The Chi square test was used to compare 
observed frequencies across two or more categories. The unpaired t-test was applied when 
comparing continuous data between groups for patient demographics.  Mann Whitney U 
and Kruskal-Wallis tests were applied to examine distributions of scores across multiple 
independent samples as appropriate. Spearman Rho correlation coefficients were used to 
assess the relationship between independent continuous variables. Multiple linear 
regression models assessed the combined effect of several variables on the mean daily RCS 
score as the major response variable. A univariate simple linear regression model was first 
developed before establishing the best fitting multivariate model according to all possible 
combinations of the variables found to be significant at p<0.01 in the univariate analysis. 
The baseline RCS diary parameters were used for analyses examining associations with 
baseline questionnaire outcomes (e.g. relationship with CSQ and PCS). The impact of season 
was assessed by pooling RCS diary returns and categorising patients according to season of 
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enrolment (Winter [1st December-February 28th], Spring [March 1st – May 31st], Summer 
[June 1st – August 31st] and Fall [September 1st – November 30th]). Local Meteorological 
Office data during the period of RCS diary collection was used to further explore the 
relationship between environmental temperature exposure and SSc-RP symptoms. The 
corresponding mean daily maximum and minimum temperatures were calculated within 
each period of RCS diary collection. 
Results 
Patient demographics and missing data 
One hundred and seven SSc patients were enrolled to the RSS (57 in Bath and 50 from 
Utah). Ninety-four patients (82 female, 14 patients with diffuse cutaneous SSc) returned 
completed baseline questionnaires. The patient demographics and clinical phenotype of the 
cohort are summarized in Table 1. The two cohorts were similar and we did not consider the 
lower age of the Utah cohort (mean of 56.4 years vs. 65.1 years) clinically meaningful or 
likely to have influenced our pooled analyses. The CSQ was adequately completed by 87 
participants and the PCS by 84 participants. Baseline RCS diaries were returned by 88 
participants (with at least one of the 3 RCS diary parameters being adequately completed in 
86 subjects). Sixty-eight subjects returned the 6-month diary (mean of 198 days [SD 76] 
between diaries]) allowing a total pooled analysis of up to 154 RCS diary returns. Adequately 
completed baseline and 6-month RCS diaries were available for 66 (70.2%) patients. A full 
breakdown of missing data is available as supplementary material online.  
Associations between patient coping strategies on SSc-RP symptom burden 
Higher scores for “praying and hoping” and “catastrophisation” domains of the CSQ were 
associated with significantly higher RCS scores (p < 0.05, Table 2) indicating a relationship 
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between these thoughts and higher burden of RP. Significantly higher RCS scores were also 
identified amongst participants reporting high utilisation of coping strategies to “re-
interpret symptoms”, and “coping self-statements” (Table 2). Efforts to effectively “ignore 
sensations” was associated with lower RCS scores (not statistically significant). There was no 
significant relationship between “increased behaviours” (doing other activities despite 
symptoms) or “diverting attention” and the distribution of the RCS scores. Fewer statistically 
significant associations were identified between coping strategies and either the 
frequency/duration of SSc-RP attacks although trends were present that mirrored the 
findings with the RCS score (Table 2). 
Association between catastrophisation and SSc-RP symptom burden 
The relationship between catastrophisation and RCS diary outcomes was replicated using 
the PCS data. When dichotomising the group (< or > a composite score of 30), “copers” had 
significantly lower median mean daily RCS scores compared to the “catastrophisers” (1.5 
[0.5-3.7] vs 4.9 [2.7-6.9], p<0.01, Table 2). Similar trends were observed for the mean daily 
frequency and duration of SSc-RP attacks. There was a moderate positive correlation 
between the total PCS and RCS scores across the cohort (Spearman’s rho 0.42, p<0.01, Table 
3). This relationship was strongest for domains concerning “helplessness” (rho 0.47) and 
“magnification” (rho 0.43) when compared to “rumination” (rho 0.35). No significant 
correlation was identified between the total PCS and frequency/duration of RP attacks 
(Table 3). Significant correlation coefficients were also identified between PCS total scores 
(and sub-domains) and patient RP VAS (rho 0.35), patient DU VAS (rho 0.33), and patient 
global VAS (rho 0.47). A weak positive correlation was identified between the total PCS and 
physician RP VAS (rho 0.23, p<0.05) but there were no other correlations with physician 
assessments. There was a positive correlation between the total PCS and the HAQ-DI (rho 
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0.42) and each of the SHAQ subscales with the exception of the SHAQ breathing VAS (Table 
3). Across all of the analyses, the association between PRO outcomes and PCS was strongest 
for the domains concerning “helplessness”.  There was no relationship between total PCS 
and disease duration, although a weak negative correlation with age (rho -0.27, p<0.05) may 
indicate partially successful adaptation with advancing years. 
Association between RCS diary responses and environmental temperature 
Using pooled data from the 154 RCS diary returns (combined baseline and 6-month data), 
there was a weak negative correlation between the mean daily RCS score and both mean 
daily maximum and minimum temperatures (Spearman’s rho -0.22, p<0.01 for both 
analyses). There were weak negative correlations between the mean daily frequency of RP 
attacks and mean daily maximum and minimum temperatures (Spearman’s rho -0.27, 
p<0.01 for both analyses). Similar trends were observed for mean daily duration of attacks 
(rho -0.26 and -0.25 respectively, p<0.01). The association between environmental 
temperatures and RCS diary outcomes was further supported when examining the 
distribution of RCS diary responses according to season of enrolment with significantly 
higher RCS diary parameters observed in Winter compared to Summer (Table 4). 
Overall determinants of the RCS score 
A multi-variate model was built to evaluate the relative contribution of all the relevant 
factors (weather, coping, other PRO outcomes, clinical features etc.) on the RCS score. A 
parametric approach was necessary for building the multivariate model, but the univariate 
findings were consistent with the non-parametric analyses presented earlier (Tables 2 and 
3). Simple linear regression identified strongly significant associations (p<0.01) between the 
RCS score and the PCS, several of the CSQ domains (particularly “catastrophisation” 
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[p<0.001] and “coping self-statements” [p=0.0044]), patient RP VAS, patient DU VAS, patient 
global VAS, HAQ-DI (and all SHAQ subscales other than breathing VAS). Univariate analysis 
did not identify significant relationships between RCS scores and physician assessments, 
age, disease duration, environmental temperatures, sex, smoking history, vasodilator use, 
history of DU or disease subset (Table 5). The individual correlations between RCS and PCS 
scores were all significant using both Spearman rho and simple linear regression. Only total 
PCS was incorporated into the multivariate model because the total PCS was perfectly 
collinear with the sum of the sub-scores and the PCS sub-scores were highly correlated 
(Pearson’s correlation > 0.7 for all pairs). The best fitting multivariate model only included 
the patient RP VAS, the SHAQ pain VAS and SHAQ GI VAS when assessing all possible 
combinations of the variables found to be significant at the at the p<0.01 level in the 
univariate analyses (Table 5). Other model selection techniques also identified these three 
predictors. The final multivariate model suggests increases in each of these PRO measures 
were significantly associated with increases in mean daily RCS. None of the coping strategy 
scores were selected in the final model, indicating that we would expect two patients with 
similar SHAQ and RP VAS scores but different coping strategies to have similar RCS diary 
responses (Table 5). 
Discussion 
We report the findings of a large study investigating the factors influencing self-report of RP 
in SSc. The overall burden of SSc-RP symptoms is not a simple linear relationship with the 
extent of digital vasoconstriction but the complex interplay of factors including, but not 
limited to, pain perception, coping strategies, catastrophisation and seasonal variation in 
weather.  
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Our study is the first to examine the relationship between coping and patient-reported SSc-
RP symptoms. Our findings confirm an earlier consensus amongst SSc experts in which 90% 
considered coping strategies to be an important determinant of RCS diary outcomes (15). 
Catastrophisation appears to be important with patients that report this behaviour (using 
both the CSQ and PCS instruments) consistently reporting a higher burden of SSc-RP 
symptoms. The direction of causality cannot easily be determined but the identified 
associations between SSc-RP severity and coping strategies (such as catastrophisation) could 
be used to develop novel behavioural approaches to by enhance resilience to reduce the 
impact of RP.  A recent large qualitative study of SSc-RP patients independently identified a 
diverse range of coping strategies (including diverting attention, ignoring sensations and 
coping self-statements) that individuals with SSc report adopting to lessen the burden of RP 
symptoms (4). These coping strategies formed an important component of an emergent 
theme around “adaptation” in the patient experience of SSc-RP and future interventions 
could capitalise on these observations (4). Cognitive-behavioural interventions that modify 
catastrophisation (specifically concerning feelings of helplessness and tendency to symptom 
magnification) could be used to reduce the burden of SSc-RP. The direction of the 
relationship between the adoption of coping strategies around “re-interpretation” and 
“coping self-statements” and RCS diary outcomes was somewhat unexpected (with patients 
reporting a higher impact of SSc-RP despite the utilisation of coping strategies within these 
domains). Nonetheless, strategies to help patients to think about their RP symptoms in 
more neutral terms (“re-interpretation”), desist from catastrophisation thoughts (such as “I 
can’t stand it anymore”) or devise positive coping self-statements (such as “No matter how 
bad it gets, I can do it” or “It won’t last much longer”) may help lessen the burden of SSc-RP. 
A similar approach has been shown to modify pain endurance in patients with other forms 
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of chronic pain (22). Intriguingly, the method chosen for inducing experimental pain in this 
work (a cold pressor test involving the immersion of hands into cold water baths) closely 
resembles the conditions and physiological responses accountable for SSc-RP symptoms. 
Other coping strategies might be less helpful in SSc-RP. For example, cognitive-behavioural 
interventions targeting “ignoring sensations” and “increasing behavioural activities” might 
result in excessive exposure to activities that might exacerbate peripheral vasoconstriction 
(23). Previous behavioural interventions for RP have examined approaches such as 
biofeedback that from a modern perspective are deemed ineffective. Behavioural 
interventions focussing on the modification of catastrophisation and coping strategies could 
be a potentially effective but hitherto neglected area of therapeutics for RP symptoms. 
Resiliency training is being increasingly used as an intervention to modify quality of life and 
function in people affected by chronic disease (24). 
Our findings also suggest that interventions targeting SSc-RP pain might be as important as 
efforts to promote peripheral vasodilation. Our multivariate analysis identified the patient 
pain VAS (from the SHAQ), the patient RP VAS and the SHAQ GI VAS as independent 
determinants of the RCS score. Whilst the association with the SHAQ GI VAS might 
represent a genuine association between RP severity and GI involvement in SSc, it is also 
possible this reflects an important shared contribution of pain/illness perception in both RP 
and GI severity self-report. Indeed, the SHAQ breathing VAS (which has no conceptual 
associations with pain) was the only SHAQ subscale not associated with RCS scores within 
the univariate analysis. Similarly, the SHAQ breathing VAS was the only subscale not to 
correlate with PCS parameters. A complex non-linear relationship between the severity of 
digital vasculopathy and pain perception may explain the poor agreement between 
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subjective (RCS diary) assessment of RP burden and objective assessment of digital vascular 
function in SSc (14, 25). 
In contrast, putative factors such as age, disease duration, disease subset, vasodilator use, 
smoking history or history of DU do not appear to be associated with patient-reported 
severity and impact of SSc-RP symptoms. The original validation work of the RCS diary 
identified differences in RCS scores (but not mean daily frequency or duration of RP attacks) 
in patients with and without DU (26). This study utilised data from a clinical trial that only 
recruited patients during the Winter months, examined differences in RCS diary parameters 
in patients with “active” DU (rather than a history of DU) and, importantly, utilised RCS 
score item wording that encouraged patients to consider the impact of “digital sores” when 
choosing their RCS score (26).  
Our findings raise additional issues relevant to the design and interpretation of SSc-RP 
clinical trials. We have confirmed a previously reported association between seasonal 
variation in environmental temperature and RP symptom burden, although our findings 
suggested a lower burden of RP symptoms in Winter than those previously reported in a 
relatively smaller study of 18 patients with SSc (6). Our findings might be of value for future 
clinical trial power calculations, particularly with respect to studies countenancing 
enrolment outside Winter. The influence of seasonal variation is not unexpected, but has 
often been overlooked in RP clinical trial design and interpretation. For example, concerns 
are frequently raised about the magnitude of the placebo response in RP clinical trials with 
one study identifying a >50% improvement in RCS scores in over a fifth of patients following 
placebo administration (5). The pooled analysis for this estimation was undertaken using 
data from 3 RCTs that enrolled at Northern-hemispheric sites during Winter with primary 
endpoint analysis in the Spring (5). Changes in environmental temperature could be an 
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important contributing factor to the placebo effect (a major hurdle to demonstrating 
efficacy within the treatment arm) and could be modified through the design of shorter RP 
clinical trials. Efforts underway to devise a novel PRO instrument for SSc-RP that is not 
reliant on diary collection may support novel clinical trial design that facilitates this (27). 
The present study benefits from being a comparatively large multi-centre study but being 
primarily a cross-sectional study and the lack of objective assessment limits the extent to 
which we can fully explore the determinants of RCS diary outcomes. Approximately 30% of 
participants did not return the 6-month RCS diary although study attrition in a longitudinal 
study of self-administered questionnaires was expected and the majority of our analyses 
utilised baseline data alone, for which there was little missing data. Our study has 
highlighted a number of factors influencing RCS diary outcomes and builds on recent work 
examining the opinions of patients and experts towards the RCS diary as a clinical trial 
endpoint (7, 15). The study has highlighted a number of factors contributing to SSc-RP 
symptom burden (such as seasonal variation in environmental temperature) that will help 
us better interpret RCS diary outcomes, inform future clinical trial design and may help 
develop novel behavioural approaches for the management of SSc-RP.  
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